Akronym/Firma	Substanz	Phase	Indikation	Beschreibung	Rekrutierung
IPF und PF-ILD STUDIEN					
Astra Zeneca Arginaut	AZD8965	IIb	Idiopathische Lungenfibrose	A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)	Aktiv
Insmed INS1009-311	Trepostinil	III	PH-ILD	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease	Aktiv
Liquidia Re-Spire_L606-301	Trepostinil	III	PH-ILD	A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Diseaase (WHO Group 3)	Aktiv
Boehringer-Ingelheim 1305-0152	Nerandomilast	IIIb	ILD	A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)	In Vorbereitung
Boehringer-Ingelheim 1305-0069	Nerandomilast	IIIb	Family ILD	A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (DROP-FPF)	Aktiv

Sarkoidose STUDIEN					
OATD-01-C03 / Molecule Kite Study	CHIT 1	II	Sarkoidose	A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase- 1 (CHITI1), for the treatment of active pulmonary sarcoidosis (the KITE study)	Aktiv
Merck Sharp & Dohme LLC	MK-7240	II	Sarkoidose	A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Active Pulmonary Sarcoidosis.	In Vorbereitung
Beobachtungsstudien / Registerstudien					
Insight-ILD / Boehringer-Ingelheim / GWD	INSIGHTS-ILD Register	NA	Idiopathische Lungenfibrose	INvestigating SIGnificant Health TrendS in Progressive Fibrosing Interstitial Lung Disease	Aktiv